Skip to main content

Venture Capital Continues To Flow Into UK Biotech In H1

The BIA/Informa Biotech Financing Update March-May 2018 was released today, revealing that the majority of funding was allocated to the post-B round. In Q2 2018, post-B funding came in at £188bn, compared to £88.9bn in Q1 2018. VC-related highlights include Oxford Nanopore Technologies raising £100mn, Benevolent AI raising £84.5mn, Crescendo Biologics raising a £57mn Series B, and Enterprise Therapeutics raising a £29mn Series B. Overall, £329.6m was raised between 1 March and 31 May 2018 via VC investments into UK biotech, for a year-to-date of £464.5m. This is on track to meet or surpass the overall 2017 total of £515mn....